(Q37650221)

21 August 2017

1 reference

title

Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience (English)

1 reference

21 August 2017

1 reference

Srilakshmi M Sharma

1

1 reference

21 August 2017

Achim R Nestel

series ordinal

2

1 reference

21 August 2017

Richard W J Lee

series ordinal

3

1 reference

21 August 2017

Andrew D Dick

series ordinal

4

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Ocular Immunology and Inflammation

21 August 2017

published in

1 reference

21 August 2017

volume

17

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

403-414

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

TNFalpha blockade in human diseases: an overview of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Pharmacological therapy for Wegener's granulomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The natural history of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The epidemiology and genetics of endogenous uveitis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Incidence of uveitis in Northern Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Causes and frequency of blindness in patients with intraocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Federal Budgetary Costs of Blindness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The role of soluble TNF receptors for TNF-alpha in uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: characterization of disease parameters and immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Interleukin-2 in the development and control of inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Clinical pharmacokinetics of TNF antagonists: how do they differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Azathioprine in Behcet's syndrome: effects on long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Biologics in the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Maintenance of medically induced remission of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The outcome of ankylosing spondylitis: a study of 100 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Biological response modifier therapy for refractory childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The cytokine network in sarcoidosis and its clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Psoriasis after treatment of juvenile idiopathic arthritis with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

The British Society for Rheumatology Biologics Register: 6 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273940903072443

10.3109/09273940903072443

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference